GMAB - Genmab A/S
After hours:
| Previous close | 40.53 |
| Open | 40.46 |
| Bid | 39.91 x 800 |
| Ask | 41.32 x 800 |
| Day's range | 40.35 - 40.79 |
| 52-week range | 26.19 - 47.50 |
| Volume | |
| Avg. volume | 434,069 |
| Market cap | 26.507B |
| Beta (5Y monthly) | 0.73 |
| PE ratio (TTM) | 35.02 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Genmab Announces Multiple Abstracts to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting and European Hematology Association (EHA) Congress
COPENHAGEN, Denmark, May 25, 2023--Genmab A/S (Nasdaq: GMAB) announced today that multiple abstracts evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, being held in Chicago, IL and virtually, June 2-6, 2023, and at the 2023 European Hematology Association (EHA) Congress, being held in Frankfurt, Germany and virtually, June 8-11, 2023.
- GlobeNewswire
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Company Announcement COPENHAGEN, Denmark; May 23, 2023 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 33,098 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1: 5,408 shares at DKK 1,025.00,547 shares at DKK 1,032.00,125 shares at DKK 1,050.00,515 shares at DKK 1,136.00,3,503
- Business Wire
EPKINLY™ (epcoritamab-bysp) Approved by U.S. Food and Drug Administration as the First and Only Bispecific Antibody to Treat Adults with Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
COPENHAGEN, Denmark, May 19, 2023--Genmab A/S (Nasdaq: GMAB) today announced that the U.S. Food and Drug Administration (FDA) has approved EPKINLY™ (epcoritamab-bysp) as the first and only T-cell engaging bispecific antibody for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS), including DLBCL arising from indolent lymphoma, and high-grade B‑cell lymphoma, after two or more lines of systemic therapy. EPKINLY wa
- GlobeNewswire
Genmab Announces Financial Results for the First Quarter of 2023
May 10, 2023 Copenhagen, Denmark; Interim Report for the First Quarter Ended March 31, 2023 Highlights Genmab revenue increased 35% compared to the first quarter of 2022, to DKK 2,854 million “In the first quarter of the year we continued to lay the groundwork for the potential approval of epcoritamab in relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Looking beyond this indication, together with our partner AbbVie Inc. (AbbVie), we are committed to a robust clinical development progr
- GlobeNewswire
Genmab To File Appeal in Its Second Arbitration Under License Agreement with Janssen
Company Announcement COPENHAGEN, Denmark; April 24, 2023 – Genmab A/S (Nasdaq: GMAB) announced today its decision to file a request for review of the award dismissing its claims in the second arbitration arising under its license agreement with Janssen Biotech, Inc. for daratumumab. The review of the award will be conducted by a single appeal arbitrator under the rules of the CPR Institute for Dispute Resolution for Non-Administered Arbitration. The arbitration remains confidential, subject to t
- GlobeNewswire
Genmab Announces Initial Resolution of Its Second Arbitration Under License Agreement with Janssen
Company Announcement COPENHAGEN, Denmark; April 21, 2023 – Genmab A/S (Nasdaq: GMAB) announced today an award in the second arbitration arising under its license agreement with Janssen Biotech, Inc. (Janssen) for daratumumab. The arbitral tribunal dismissed Genmab’s claims, on the basis that they should have been brought in the first arbitration. One of the three arbitrators dissented. Genmab has the right to seek review of the award, which it must do within a limited period of time. Genmab is c
- GlobeNewswire
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2023
Company Announcement Net sales of DARZALEX® in the first quarter of 2023 totaled USD 2,264 millionGenmab receives royalties on worldwide net sales from Janssen Biotech, Inc. (Janssen) COPENHAGEN, Denmark; April 18, 2023 – Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX® (daratumumab), including sales of the subcutaneous (SC) product (daratumumab and hyaluronidase-fihj, sold under the tradename DARZALEX FASPRO® in the U.S.), as reported by Johnson & Johnson we
- GlobeNewswire
Genmab and argenx Enter Partnership to Advance Antibody Therapies in Immunology and Oncology
Media ReleaseCOPENHAGEN, Denmark; April 17, 2023 Genmab and argenx have entered a multiyear collaboration bringing together capabilities to jointly discover, develop and commercialize antibody therapiesDiscovery programs against two differentiated targets are underway Genmab A/S (Nasdaq: GMAB) and argenx (Euronext & Nasdaq: ARGX) announced today that Genmab and argenx have entered into a collaboration agreement to jointly discover, develop and commercialize novel therapeutic antibodies with appl
- GlobeNewswire
Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons
Company Announcement COPENHAGEN, Denmark; April 6, 2023 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) made by managerial employees and their closely associated persons. The company’s managerial employees and their closely associated persons have given Genmab A/S power of attorney on their behalf to publish trading in
- GlobeNewswire
Completion of share buy-back program
Company Announcement COPENHAGEN, Denmark; April 3, 2023 – Genmab A/S (Nasdaq: GMAB) announces that its share buy-back program has been completed on March 31, 2023. On February 22, 2023, Genmab announced the initiation of a share buy-back program to honor our commitments under our Restricted Stock Unit program. The share buy-back program was expected to be completed no later than March 31, 2023, and to comprise up to 220,000 shares. The following transactions were executed under the program from
- GlobeNewswire
Constitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab
Company Announcement COPENHAGEN, Denmark; March 29, 2023 – Genmab A/S (Nasdaq: GMAB) Following Genmab A/S’ Annual General Meeting held on March 29, 2023, the Company’s Board of Directors met to constitute itself. Ms. Deirdre P. Connelly was appointed Chair and Ms. Pernille Erenbjerg was appointed Deputy Chair. It was decided to grant 90,054 restricted stock units to members of management and employees of the Company and the Company’s subsidiaries and 16,276 warrants to the employees of the Compa
- GlobeNewswire
Passing of Genmab A/S’ Annual General Meeting
Company Announcement At Genmab A/S’ Annual General Meeting held today March 29, 2023, the Annual Report for 2022 was approvedDischarge was given to the Board of Directors and the Executive Management and the year’s profit was carried forwardThe 2022 Compensation Report was approvedSix members of the Board of Directors were re-electedPricewaterhouseCoopers was re-elected as auditor of the CompanyThe proposals from the Board of Directors on the Board of Directors' remuneration for 2023, the propos
- GlobeNewswire
Genmab Announces Appointment of Martine van Vugt to Chief Strategy Officer
Media ReleaseCOPENHAGEN, Denmark; March 28, 2023 Genmab A/S (Nasdaq: GMAB) announced today that Martine van Vugt has been appointed to Chief Strategy Officer and promoted to Executive Vice President effective March 29, 2023. Martine will oversee Corporate Strategy, Corporate Development, Business Development and Licensing and Alliance Management. Martine joined Genmab in 2001 and most recently served as Genmab’s Senior Vice President, Corporate Strategy & Planning. She will continue her role as
- GlobeNewswire
Transactions in connection with share buy-back program
Company Announcement COPENHAGEN, Denmark; March 27, 2023 – Genmab A/S (Nasdaq: GMAB). On February 22, 2023, Genmab announced the initiation of a share buy-back program to honor our commitments under our Restricted Stock Units program. The share buy-back program is expected to be completed no later than March 31, 2023, and comprises up to 220,000 shares. The following transactions were executed under the program from March 20, 2023, to March 24, 2023: No. of sharesAverage price (DKK)Total value (
- GlobeNewswire
Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab
Company Announcement COPENHAGEN, Denmark; February 24, 2023 – Genmab A/S (Nasdaq: GMAB) announced today that the board decided to grant 177,774 restricted stock units to members of management and employees of the company as well as the company's subsidiaries and 164,333 warrants to employees of the company and the company's subsidiaries. Each restricted stock unit is awarded cost-free and provides the owner with a right and obligation to receive one share in Genmab A/S of nominally DKK 1. The re
- GlobeNewswire
Notice to Convene the Annual General Meeting of Genmab A/S
Company Announcement Genmab A/S to hold Annual General Meeting on Wednesday March 29, 2023 COPENHAGEN, Denmark; February 23, 2023 – Genmab A/S (Nasdaq: GMAB) summons the Annual General Meeting on Wednesday, March 29, 2023, at 2:00 PM CEST at the Copenhagen Marriott Hotel, Kalvebod Brygge 5, DK-1560 Copenhagen V, Denmark. The notice for the Annual General Meeting, including Appendix 1: Candidates for the Board of Directors, and Appendix 2: Proposed amended Remuneration Policy is attached. About G
- GlobeNewswire
Genmab Files Annual Report with the U.S. Securities and Exchange Commission
Media ReleaseCopenhagen, Denmark, February 22, 2023 Genmab filed Form 20-F for the financial year 2022 with the U.S. SEC Genmab A/S (Nasdaq: GMAB) announced today that it has filed its Annual Report for the financial year 2022 on Form 20-F with the U.S. Securities and Exchange Commission (SEC), incorporating by reference parts of the Genmab A/S Annual Report 2022. Both reports are available via the SEC’s website, www.sec.gov and Genmab’s website, www.genmab.com. About Genmab Genmab is an interna
- GlobeNewswire
Genmab Announces Initiation of Share Buy-Back Program
Company Announcement Repurchase of up to 220,000 sharesHonoring commitments under our Restricted Stock Unit programCompletion expected on March 31, 2023 COPENHAGEN, Denmark; February 22, 2023 – Genmab A/S (Nasdaq: GMAB) announced today that it is initiating a share buy-back program to honor our commitments under our Restricted Stock Unit program. The share buy-back program will be undertaken on the terms set out below and in accordance with Regulation (EU) No. 596/2014 (‘MAR’) and the Commission
- GlobeNewswire
Genmab Publishes 2022 Annual Report
Company Announcement COPENHAGEN, Denmark; February 22, 2023 – Genmab A/S (Nasdaq: GMAB) announced today the publication of its Annual Report for 2022. Below is a summary of business progress in 2022, financial performance for the year and the financial outlook for 2023. The full report is attached as a PDF file and in iXBRL format and can be found in the investor section of the company’s website, www.genmab.com/investors. Conference CallGenmab will hold a conference call in English to discuss th
- GlobeNewswire
Grant of Restricted Stock Units and Warrants to Employees in Genmab
Company Announcement COPENHAGEN, Denmark; January 24, 2023 – Genmab A/S (Nasdaq: GMAB) announced today that the Board decided to grant 5,408 restricted stock units to employees of the Company as well as the Company’s subsidiaries and 5,138 warrants to employees of the Company and the Company's subsidiaries. Each restricted stock unit is awarded cost-free and provides the owner with a right and obligation to receive one share in Genmab A/S of nominally DKK 1. The fair value of each restricted sto
- GlobeNewswire
Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2022
Company Announcement Net sales of DARZALEX® in 2022 totaled USD 7,977 millionGenmab receives royalties on worldwide net sales from Janssen Biotech, Inc. (Janssen) COPENHAGEN, Denmark; January 24, 2023 – Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX® (daratumumab), including sales of the subcutaneous (SC) product (daratumumab and hyaluronidase-fihj, sold under the tradename DARZALEX FASPRO® in the U.S.), as reported by Johnson & Johnson were USD 7,977 millio
- GlobeNewswire
Correction to Company Announcement No. 1 of January 3, 2023
Company Announcement COPENHAGEN, Denmark; January 19, 2023 – Genmab A/S (Nasdaq: GMAB) Correction: In company announcement no. 1/2023 regarding transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons it was reported that member of the Board of Directors, Mijke Zachariasse, acquired a total of 175 shares in Genmab A/S due to vesting of restricted stock units (partly as employee of Genmab B.V., partly as board member). The corr
- GlobeNewswire
Genmab to Present at the 41st Annual J.P. Morgan Healthcare Conference
Media ReleaseCOPENHAGEN, Denmark; January 2, 2023Genmab A/S (Nasdaq: GMAB) announced today that its CEO, Jan van de Winkel, Ph.D., will present a company update at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco at 9:00 AM PST / 12:00 PM EST / 6:00 PM CET on January 11, 2023. The live and archived webcast of the presentation will be available on Genmab’s website at https://ir.genmab.com/events-and-presentations#content. About Genmab Genmab is an international biotechnology com
- Business Wire
Genmab Announces Submission of Japan New Drug Application (JNDA) for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL)
COPENHAGEN, Denmark, December 21, 2022--Genmab A/S (Nasdaq: GMAB):
- GlobeNewswire
Genmab to Hold 2022 R&D Update and ASH Data Review Meeting
Media Release Event to be held live in New Orleans, LouisianaMeeting to be webcast live and archived on www.genmab.com Copenhagen, Denmark; December 12, 2022 – Genmab A/S (Nasdaq: GMAB) will hold its 2022 R&D Update and ASH Data Review Meeting today, December 12, 2022 at 8:00 PM Eastern Time (7:00 PM CST / 1:00 AM GMT on December 13). The event will take place live at the Four Seasons New Orleans in New Orleans, Louisiana, Plimsole Ballroom B. Those wishing to attend in person may register on si
